Biomarker & Genomic Testing

A Blood Test's Blind Spots: Discrepancies Between P-tau217 and Clinical Alzheimer's Disease

George Padron
Precision Medicine, Biomarker & Genomic Testing, Neurology & Mental Health, Alzheimer's & Dementia | Aug 1, 2026
P-tau217 was identified as the strongest blood marker for clinical Alzheimer's disease in a study of 1,817 Caribbean Hispanic adults; however, 37% of diagnosed patients tested negative.

Barrett's Surveillance Shifts to a Risk-Based Footing

George Padron
Oncology Care, Biomarker & Genomic Testing, GI Cancers, Population Health Management | Jul 30, 2026
AGA's new Barrett's esophagus guideline replaces uniform surveillance with risk-based intervals and names high-quality endoscopy as the key to cancer prevention.

Only Healthcare: How AI Can Wed Personalized Care to Authorization (Part 1)

George Padron
Podcasts, Biomarker & Genomic Testing, Digital Health & AI, Managed Care, Value Based Care | Jun 22, 2026
Randy Vogenburg, PhD, discusses AI's integration of personalized care and authorization in healthcare with Tamara Thomas. (Part 1)

PSA Screening Prostate Cancer Evidence Review

George Padron
Oncology Care, Biomarker & Genomic Testing, GU Cancers | Jun 20, 2026
An updated Cochrane review of almost 800,000 men finds PSA screening likely reduces prostate cancer deaths, about one per 500 invited, set against overdiagnosis risk.

Datopotamab Deruxtecan Anchors Post-TKI Care in EGFR-Mutant Lung Cancer, MSK Oncologist Says

George Padron
Oncology Care, Biomarker & Genomic Testing, Specialty Medicine, Lung & Thoracic, Pulmonology | May 20, 2026
MSK's Helena Yu describes how datopotamab deruxtecan now anchors post-TKI care for EGFR-mutant lung cancer when no targetable resistance mechanism is found on re-biopsy